Get the Stockscreener App
12.44
4.27%
0.51
Design Therapeutics Inc stock is traded at $12.44, with a volume of 1.04M.
It is up +4.27% in the last 24 hours and up +16.26% over the past month.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.
See More
Previous Close:
$11.93
Open:
$12.18
24h Volume:
1.04M
Relative Volume:
1.41
Market Cap:
$776.96M
Revenue:
-
Net Income/Loss:
$-69.71M
P/E Ratio:
-10.42
EPS:
-1.1935
Net Cash Flow:
$-54.12M
1W Performance:
+18.14%
1M Performance:
+16.26%
6M Performance:
+38.07%
1Y Performance:
+228.23%
1-Day Range:
$11.93
$12.68
1-Week Range:
$10.45
$12.68
52-Week Range:
$3.33
$17.25
Design Therapeutics Inc Stock (DSGN) Company Profile
Name
Design Therapeutics Inc
Sector
Industry
Phone
858-293-4900
Address
6005 HIDDEN VALLEY ROAD, CARLSBAD
Compare DSGN vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DSGN
Design Therapeutics Inc
|
12.44 | 776.96M | 0 | -69.71M | -54.12M | -1.1935 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Design Therapeutics Inc Stock (DSGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-16-26 | Initiated | Jefferies | Buy |
| Jan-07-26 | Initiated | Oppenheimer | Outperform |
| Dec-03-25 | Initiated | Craig Hallum | Buy |
| Dec-03-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Nov-20-25 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| May-07-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Nov-14-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-15-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Aug-15-23 | Downgrade | SVB Securities | Outperform → Market Perform |
| Aug-15-23 | Downgrade | Wedbush | Outperform → Neutral |
| May-04-23 | Upgrade | Goldman | Sell → Neutral |
| Jun-10-22 | Initiated | Wedbush | Outperform |
| May-02-22 | Initiated | RBC Capital Mkts | Outperform |
| Jan-19-22 | Initiated | Goldman | Sell |
| Apr-20-21 | Initiated | Goldman | Neutral |
| Apr-20-21 | Initiated | Piper Sandler | Overweight |
| Apr-20-21 | Initiated | SVB Leerink | Outperform |
View All
Design Therapeutics Inc Stock (DSGN) Latest News
Design Therapeutics Inc (DSGN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Design Therapeutics Inc (DSGN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Design Therapeutics Inc (DSGN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Design Therapeutics Inc (DSGN) Institutional Confidence - TradingKey
Design Therapeutics Inc (DSGN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Design Therapeutics Inc (DSGN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Design Therapeutics Inc (DSGN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Design Therapeutics Inc (DSGN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Design Therapeutics Inc (DSGN) Valuation: PE, PB & Fair Value Analysis - TradingKey
Design Therapeutics (DSGN) Gains 2.28% – Approaching Key Resistance at $11.78Weekly Profile - newsline.com
DSGN Q1 2026 Earnings: EPS Beat as Net Loss NarrowsEarnings Expansion Phase - newsline.com
Design Therapeutics Stockholders Approve Director and Auditor at Meeting - TipRanks
Design Therapeutics (DSGN) grants George Simeon 30,000 stock options at $10.55 - Stock Titan
[Form 4] Design Therapeutics, Inc. Insider Trading Activity - Stock Titan
Design Therapeutics (DSGN) director awarded 30,000 options at $10.55 strike - Stock Titan
Director at Design Therapeutics (DSGN) awarded options on 30,000 shares - Stock Titan
Design Therapeutics (DSGN) grants director David Shapiro 30,000 options - Stock Titan
Director at Design Therapeutics (DSGN) awarded 30,000 stock options - Stock Titan
Design Therapeutics (NASDAQ: DSGN) details outcomes of 2026 shareholder meeting votes - Stock Titan
Enliven Therapeutics Announces Updated Positive Phase 1 Clinical Data and Alignment with FDA on Key Phase 3 Trial Design Components - PR Newswire
DSGN Q1 2026 Earnings: Narrower-than-expected loss highlights cost disciplineSubscription Growth Report - newsline.com
Point72-affiliated holders report 5.1% stake in Design Therapeutics (DSGN) - Stock Titan
Are Medical Stocks Lagging Atea Pharmaceuticals (AVIR) This Year? - Yahoo Finance
DESIGN THERAPEUTICS INC (DSGN) Stock Chart - ChartMill
DSGN: Early clinical data in Friedreich's ataxia support rapid advancement to registrational studies - TradingView
Alnylam and Inceptive Form Strategic AI Collaboration to Accelerate the Discovery of RNAi Therapeutics - Business Wire
Design Therapeutics Drops Ahead of Jefferies, Trial Remains in Focus for DSGN - Bez Kabli
Waypoint Bio Raises $20M Series A Led by Amplify Partners to Advance AI-Designed Cell Therapies Toward the Clinic - Business Wire
Design Therapeutics (DSGN) Slides 2.42% as Biotech Stock Tests Key SupportButterfly Setup - The Legal Advocate
Design Therapeutics (DSGN) Dips as Key Support Holds After 2.42% DeclineNaked POC - The Legal Advocate
Design Therapeutics shares jump on encouraging Friedreich ataxia trial results (DSGN) - MSN
Design Therapeutics to Participate in 2026 Jefferies Global Healthcare Conference - The Manila Times
Biotech Design Therapeutics to join Jefferies 2026 healthcare fireside chat - Stock Titan
Piper Sandler Reaffirms Their Buy Rating on Design Therapeutics (DSGN) - The Globe and Mail
Piper Sandler Maintains Design Therapeutics(DSGN.US) With Buy Rating, Maintains Target Price $20 - Moomoo
DSGN Q1 2026 Earnings: Narrower-Than-Expected Loss as Cost Discipline ContinuesPeak Earnings Alert - newsline.com
Design Therapeutics(DSGN) Stock Options Chain | Quotes & News - Moomoo
Design Therapeutics (DSGN) Consolidates Near Support After Marginal DeclineMonthly Profile - The Legal Advocate
Design Therapeutics (DSGN) Holds Steady Near Support as Consolidation PersistsVerified Analyst Reports - Newser
Design Therapeutics Inc. (DSGN) Q1 2026 Earnings: Narrower Loss Surpasses Expectations Amid Quiet QuarterGuidance Accuracy Score - Newser
Design Therapeutics (DSGN) price target increased by 17.05% to 17.51 - MSN
Design Therapeutics (DSGN) Edges Higher as Support Holds Above $10.60Social Trading Insights - Newser
Design Therapeutics Inc. (DSGN) Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Progress in Gene Therapy PipelineRevenue Inflection Point - Newser
Analysts Conflicted on These Healthcare Names: Design Therapeutics (DSGN), Pro Medicus Limited (OtherPMCUF) and Boston Scientific (BSX) - The Globe and Mail
BlossomHill Therapeutics Expands Board of Directors with the Appointments of Sheila Gujrathi, M.D., and John Schmid - The Manila Times
DT-216P2 Shows Dose-Dependent Frataxin Increases and Clinical Improvements After 4 Weeks of IV Dosing in Friedreich Ataxia - Neurology Live
RBC Capital Maintains Design Therapeutics(DSGN.US) With Buy Rating, Raises Target Price to $20 - Moomoo
Craig-Hallum Maintains Design Therapeutics(DSGN.US) With Buy Rating, Raises Target Price to $22 - Moomoo
Design Therapeutics stock wobbles after rare genetic disease data - MSN
Design Therapeutics, Inc. (DSGN) Discusses Data from RESTORE-FA Trial of DT-216P2 for Friedreich AtaxiaSlideshow (NASDAQ:DSGN) 2026-05-19 - Seeking Alpha
Nasdaq Down 200 Points; Brady Earnings Top Views - Sahm
Design Therapeutics Inc Stock (DSGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.74%
1.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):